Team Grant : CIHR-JDRF Type 1 Diabetes and Precision Medicine – Full Application
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: inquire with unit
Memorial Deadline: Thursday 18th, August 2022
External Deadline: Tuesday 23rd, August 2022
Description
Precision medicine is an important “approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle”1. Often described as the provision of the right treatment for the right patient at the right time, precision medicine focuses on integrating multidimensional data about genetic, molecular, and environmental factors to improve disease diagnosis, care, treatment or prevention.
Type 1 diabetes (T1D) is caused by a myriad of factors that lead to the destruction of insulin-producing pancreatic beta cells, and the current treatment approach using exogenous insulin replacement therapy does not adequately consider its complex pathophysiology. Limited understanding of the heterogeneity of T1D is a major barrier that prevents new translational research from influencing therapy development and slows the introduction of new treatment options into clinical practice 2.
Greater understanding of how individual characteristics ‒ including in genetic profiles, biomarkers and immune and beta cell dysfunction ‒ contribute to T1D risk and progression may lead to identification of more precise therapeutic targets, better characterization of disease risk, initiation and progression, improved opportunities for safe and effective intervention and, ultimately, prevention of T1D. T1D risk and progression are influenced by genetics and environmental factors. While genomic variants have been found to be associated with T1D risk in individuals of European ancestry, mechanisms underlying these associations are largely unknown, and racial and ethnic minorities have been commonly under-represented in this type of research 3.
The advancement of precision medicine approaches for T1D will allow health care providers to tailor clinical care and help to accelerate the development of new therapeutics to improve outcomes for people with T1D or delay the onset of the disease in at-risk individuals. Building on the expertise developed through CIHR’s Personalized Health Initiative and complementing previous CIHR and JDRF investments in new research as part of 100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes, the CIHR-JDRF Type 1 Diabetes and Precision Medicine will support multi-disciplinary research to characterize disease heterogeneity and accelerate precision medicine approaches for prediction, prevention or treatment of T1D.
| Competition | 202208TDP |
|---|---|
| Registration Deadline | 2022-07-21 |
| Application Deadline | 2022-08-23 |
See ResearchNet for more information.